CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Fecal Calprotectin Testing in Adults

Policies governing coverage of fecal calprotectin testing for adults (age ≥18) to distinguish inflammatory bowel disease from non-inflammatory GI disorders and to monitor IBD response/relapse; applies to Blue Cross Blue Shield - Tennessee members per benefit specifics.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyFecal Calprotectin Testing in Adults

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument patient's age (≥18) and clinical indication (differential diagnosis of IBS vs IBD or monitoring response/relapse of IBD) when requesting testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18Age group

50 µg/gCommon cutoff

150 µg/gUC monitoring cutoff

>90%Diagnostic accuracy

83993Procedure code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Fecal Calprotectin Testing

Not Medically Necessary / Not Covered

Not covered indications: Any indication not explicitly listed as covered (i.e., situations other than differential diagnosis between IBS and IBD or monitoring/assessment of IBD response/relapse)

Does not meet coverage criteria due to lack of supporting published scientific literature

Use in diagnosis and monitoring of IBD

Covered when consistent with guideline-recommended use and clinical context

Monitoring disease activity and mucosal healing: Fecal calprotectin can be used to monitor disease activity, assess response to therapy, and as a noninvasive surrogate for mucosal healing; in UC, assessment for mucosal healing by fecal calprotectin is appropriate approximately 3 to 6 months after treatment initiation.3-6 months assessment interval

Per ECCO and Maaser et al. recommendations regarding monitoring and timing for assessment of mucosal healing.

This policy applies only to individuals 18 years of age or older. Testing requests for members under 18 do not fall under these coverage criteria and will be handled outside this policy.

Rapid point-of-care fecal calprotectin assays that are available internationally (for example, CalproSmart™) have not been approved for use in the United States by the FDA. Such international POC tests are not considered FDA-cleared for use in U.S. members under this policy.

Fecal calprotectin testing is considered not medically necessary for any indications not explicitly listed as covered in this policy (i.e., other than differentiating non‑inflammatory gastrointestinal disease from inflammatory disease, or assessing/monitoring response and relapse in IBD).

Fecal calprotectin should not be used in isolation to make diagnostic or management decisions. Results must be interpreted in the context of clinical evaluation and other diagnostic procedures (for example, endoscopy and standard laboratory markers); guideline guidance supports using calprotectin as part of a stepwise assessment rather than as the sole arbiter of care.

Coding and Thresholds

Covered CPT Codes (referenced)CPTCovered

83993

Calprotectin, fecal

Common calprotectin thresholds mentioned

Common manufacturer cutoff50 µg/g

AGA / monitoring threshold frequently cited150 µg/g

Intermediate/test-specific cutoffs reported100 µg/g

Higher cutoffs used in some studies200 µg/g

Other study-specific cutoffs (examples)139 µg/g; 160 µg/g

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for fecal calprotectin testing (CPT 83993) when applicable under the member's benefit plan. Providers should obtain authorization before performing testing to avoid potential claim denials. Include the clinical indication and relevant prior testing or treatment history with the authorization request.

Affected code: CPT 83993 (Calprotectin, fecal)
Ensure prior auth is consistent with member benefits and plan-specific rules

Documentation Required

Conformance with Government Policies

This policy defers to applicable state and federal regulations and coverage determinations. If there is any conflict between this policy and a relevant government policy (for example, Medicare Local Coverage Determinations [LCDs] or National Coverage Determinations [NCDs], or state Medicaid rules), the government policy will govern the coverage decision. Review and follow the most current LCDs/NCDs and state Medicaid guidance when they apply to the member.

Background and Rationale

Calprotectin is a neutrophil-derived protein that is excreted in stool and rises in the presence of intestinal inflammation. Measurement of fecal calprotectin provides a noninvasive marker of colonic/mucosal inflammation and is useful to help distinguish inflammatory bowel disease (IBD) from non‑inflammatory conditions such as irritable bowel syndrome (IBS), to monitor disease activity, to assess response to therapy, and to help detect relapse.

Definitions

Fecal calprotectin — definition and clinical use

DefinitionFecal calprotectin (FC, FCAL): a neutrophil-derived protein measured in stool that serves as a noninvasive biomarker of intestinal mucosal inflammation.

Biologic sourceDerived from neutrophils, monocytes, and macrophages and released into the intestinal lumen during mucosal inflammation.

Clinical useUsed to distinguish inflammatory bowel disease (IBD) from non-inflammatory disorders (e.g., IBS) and to monitor disease activity, response to therapy, and relapse detection.

Analytic notesMeasured by quantitative or qualitative immunoassays (polyclonal or monoclonal antibody–based); several FDA-cleared platforms exist.

IBD — definition

Definition

Note

Clinical Sequencing and Role in Evaluation/Monitoring

Fecal calprotectin testing should be used as part of a guideline-recommended, stepwise clinical evaluation. Appropriate clinical sequencing includes using fecal calprotectin to help differentiate inflammatory bowel disease (IBD) from non-inflammatory conditions (e.g., IBS) in adults, and as a monitoring tool to assess response to therapy or detect relapse in patients with known IBD. Consider fecal calprotectin measurement alongside clinical assessment, endoscopy with biopsy, and cross-sectional imaging per society guidance (e.g., AGA, Maaser et al.). Serial calprotectin monitoring may be appropriate for indeterminate results or for ongoing monitoring in patients with mild symptoms.

Use calprotectin to distinguish IBD vs IBS in adults with new lower GI symptoms when cancer is not suspected
In IBD, use calprotectin for monitoring response to therapy and for relapse surveillance (typically as part of 3–6 month assessments where indicated)
Follow a stepwise approach: fecal calprotectin → endoscopy with biopsy and/or cross-sectional imaging as clinically indicated
Consider serial monitoring for indeterminate values or mild symptoms